Company intelligence / Profile preview

MAV

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

MAV Therapeutics was a biotechnology company focused on developing novel therapies targeting the Mitochondrial Antiviral Signaling (MAVS) protein pathway. The company's research centered on modulating MAVS to treat a variety of autoimmune and inflammatory conditions by regulating the body's innate immune response. MAV Therapeutics aimed to leverage its expertise in the MAVS pathway to create first-in-class small molecule inhibitors. In 2021, the company was acquired by Biohaven Pharmaceutical Holding Company Ltd. to bolster its neuro-innovation and immunology pipeline.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MAV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAV.

Explore the full profile